María Eugenia Soria

María Eugenia Soria

Auto-generated profile, based on publicly available information

María Eugenia Soria

Centro de Biología Molecular Severo Ochoa (CBM), (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid) (CSIC-UAM), Campus de Cantoblanco

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
CPCelia Perales
Celia Perales
NBNathan M. Beach
Nathan M. Beach
IGIsabel Gallego
Isabel Gallego
MSMaria Eugenia Soria
Maria Eugenia Soria
JQJosep Quer
Josep Quer
JSJulie Ann Sheldon
Julie Ann Sheldon
Cell culture-produced hepatitis C virus (HCV) has been subjected to up to 100 serial passages in human hepatoma cells in the absence or presence of different doses of alpha interferon (IFN-α). Virus survival, genetic changes, fitness levels, and phenotypic traits have been examined. While high initial IFN-α doses (increasing from 1 to 4 IU/ml) did not allow HCV survival beyond passage 40, a gradual exposure (from 0.25 to 10 IU/ml) allowed the virus to survive for at least 100 passages. The virus passaged in the presence of IFN-α acquired IFN-α resistance as evidenced by enhanced progeny production and viral protein expression in an IFN-α environment. A partial IFN-α resistance was also noted in populations passaged in the absence of IFN-α. All lineages acquired adaptative mutations, and multiple, nonsynonymous mutations scattered throughout the genome were present in IFN-α-selected populations. Comparison of consensus sequences indicates a dominance of synonymous versus nonsynonymous substitutions. IFN-α-resistant populations displayed decreased sensitivity to a combination of IFN-α and ribavirin. A phenotypic trait common to all assayed viral populations is the ability to increase shutoff host cell protein synthesis, accentuated in infections with IFN-α-selected populations carried out in the presence of IFN-α. The trait was associated with enhanced phosphorylation of protein kinase R (PKR) and eIF2α, although other contributing factors are likely. The results suggest that multiple, independent mutational pathways can confer IFN-α resistance to HCV and might explain why no unified picture has been obtained regarding IFN-α resistancein vivo.

18 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AÁAna I De Ávila
Ana I De Ávila
IGIsabel Gallego
Isabel Gallego
MSMaria Eugenia Soria
Maria Eugenia Soria
Josep GregoriJosep Gregori
Josep Gregori
JQJosep Quer
Josep Quer
CPCelia Perales
Celia Perales
Lethal mutagenesis is an antiviral approach that consists in extinguishing a virus by an excess of mutations acquired during replication in the presence of a mutagen. Here we show that favipiravir (T-705) is a potent mutagenic agent for hepatitis C virus (HCV) during its replication in human hepatoma cells. T-705 leads to an excess of G → A and C → U transitions in the mutant spectrum of preextinction HCV populations. Infectivity decreased significantly in the presence of concentrations of T-705 which are 2- to 8-fold lower than its cytotoxic concentration 50 (CC50). Passaging the virus five times in the presence of 400 μM T-705 resulted in virus extinction. Since T-705 has undergone advanced clinical trials for approval for human use, the results open a new approach based on lethal mutagenesis to treat hepatitis C virus infections. If proven effective for HCV in vivo, this new anti-HCV agent may be useful in patient groups that fail current therapeutic regimens.

1 July 2019 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
CPCelia Perales
Celia Perales
IGIsabel Gallego
Isabel Gallego
AÁAna Isabel de Ávila
Ana Isabel de Ávila
MSMaría Eugenia Soria
María Eugenia Soria
Josep GregoriJosep Gregori
Josep Gregori
EDEsteban Domingo
Esteban Domingo
Selection of viral mutants resistant to compounds used in therapy is a major determinant of treatment failure, a problem akin to antibiotic resistance in bacteria. In this scenario, mutagenic base ...

15 May 2017 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
EMElena Moreno
Elena Moreno
IGIsabel Gallego
Isabel Gallego
Josep GregoriJosep Gregori
Josep Gregori
ALAdriana Lucía-Sanz
Adriana Lucía-Sanz
MSMaría Eugenia Soria
María Eugenia Soria
CPCelia Perales
Celia Perales
Viral quasispecies evolution upon long-term virus replication in a noncoevolving cellular environment raises relevant general issues, such as the attainment of population equilibrium, compliance with the molecular-clock hypothesis, or stability of the phenotypic profile. Here, we evaluate the adaptation, mutant spectrum dynamics, and phenotypic diversification of hepatitis C virus (HCV) in the course of 200 passages in human hepatoma cells in an experimental design that precluded coevolution of the cells with the virus. Adaptation to the cells was evidenced by increase in progeny production. The rate of accumulation of mutations in the genomic consensus sequence deviated slightly from linearity, and mutant spectrum analyses revealed a complex dynamic of mutational waves, which was sustained beyond passage 100. The virus underwent several phenotypic changes, some of which impacted the virus-host relationship, such as enhanced cell killing, a shift toward higher virion density, and increased shutoff of host cell protein synthesis. Fluctuations in progeny production and failure to reach population equilibrium at the genomic level suggest internal instabilities that anticipate an unpredictable HCV evolution in the complex liver environment. IMPORTANCE Long-term virus evolution in an unperturbed cellular environment can reveal features of virus evolution that cannot be explained by comparing natural viral isolates. In the present study, we investigate genetic and phenotypic changes that occur upon prolonged passage of hepatitis C virus (HCV) in human hepatoma cells in an experimental design in which host cell evolutionary change is prevented. Despite replication in a noncoevolving cellular environment, the virus exhibited internal population disequilibria that did not decline with increased adaptation to the host cells. The diversification of phenotypic traits suggests that disequilibria inherent to viral populations may provide a selective advantage to viruses that can be fully exploited in changing environments.

1 February 2020 in Antiviral Research
Verified
Journal Article
Closed access
QCQian Chen
Qian Chen
CPCelia Perales
Celia Perales
MSMaría Eugenia Soria
María Eugenia Soria
DGDamir García-Cehic
Damir García-Cehic
Josep GregoriJosep Gregori
Josep Gregori
JQJosep Quer
Josep Quer

3 September 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMaría Eugenia Soria
María Eugenia Soria
Josep GregoriJosep Gregori
Josep Gregori
QCQian Chen
Qian Chen
DGDamir Garcia-Cehic
Damir Garcia-Cehic
MLMeritxell Llorens
Meritxell Llorens
CPCelia Perales
Celia Perales
Despite the high sustained virological response rates achieved with current directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5–10% of treated patients do not respond to current antiviral therapies, and basal resistance to DAAs is increasingly detected among treatment-naïve infected individuals. Identification of amino acid substitutions (including those in minority variants) associated with treatment failure requires analytical designs that take into account the high diversification of HCV in more than 86 subtypes according to the ICTV website (June 2017). The methodology has involved five sequential steps: (i) to design 280 oligonucleotide primers (some including a maximum of three degenerate positions), and of which 120 were tested to amplify NS3, NS5A-, and NS5B-coding regions in a subtype-specific manner, (ii) to define a reference sequence for each subtype, (iii) to perform experimental controls to define a cut-off value for detection of minority amino acids, (iv) to establish bioinformatics’ tools to quantify amino acid replacements, and (v) to validate the procedure with patient samples. A robust ultra-deep sequencing procedure to analyze HCV circulating in serum samples from patients infected with virus that belongs to the ten most prevalent subtypes worldwide: 1a, 1b, 2a, 2b, 2c, 2j, 3a, 4d, 4e, 4f has been developed. Oligonucleotide primers are subtype-specific. A cut-off value of 1% mutant frequency has been established for individual mutations and haplotypes. The methodological pipeline described here is adequate to characterize in-depth mutant spectra of HCV populations, and it provides a tool to understand HCV diversification and treatment failures. The pipeline can be periodically extended in the event of HCV diversification into new genotypes or subtypes, and provides a framework applicable to other RNA viral pathogens, with potential to couple detection of drug-resistant mutations with treatment planning.